思创医惠(300078) - 2022 Q1 - 季度财报

Revenue and Profit - Revenue for Q1 2022 was CNY 386,055,693.36, an increase of 17.29% compared to CNY 329,145,737.18 in the same period last year[3] - Net profit attributable to shareholders decreased by 1.62% to CNY 30,953,691.43 from CNY 31,462,503.73 year-on-year[3] - Net profit excluding non-recurring gains and losses increased by 28.76% to CNY 28,421,187.63 from CNY 22,073,223.29 in the previous year[3] - The net profit for the first quarter was CNY 29,120,333.27, slightly up from CNY 28,885,512.16 year-over-year[23] - The total comprehensive income for the period was CNY 34,283,586.04, compared to CNY 29,146,196.72 in the previous period, representing an increase of approximately 17.3%[24] - The company reported a basic and diluted earnings per share of CNY 0.04, unchanged from the previous period[24] Cash Flow and Liquidity - The net cash flow from operating activities improved by 20.71%, reaching CNY -143,017,748.92 compared to CNY -180,371,345.32 in the same period last year[3] - Cash inflows from operating activities totaled CNY 310,194,960.39, while cash outflows were CNY 453,212,709.31, resulting in a net cash outflow of CNY 143,017,748.92[27] - The company’s cash and cash equivalents at the end of the period amounted to RMB 602,128,724.94, down from RMB 781,443,391.33 at the beginning of the year[18] - The ending balance of cash and cash equivalents was CNY 545,302,406.44, down from CNY 891,904,820.37 in the previous period[28] - The net cash flow from investing activities was -CNY 60,478,698.47, an improvement from -CNY 191,269,571.27 in the previous period[27] - The total cash inflow from financing activities was CNY 135,000,000.00, compared to CNY 1,020,490,000.00 in the previous period, reflecting a significant decrease of approximately 86.8%[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,833,304,674.06, a decrease of 0.62% from CNY 4,863,530,760.78 at the end of the previous year[3] - The total liabilities decreased to CNY 2,596,636,001.92 from CNY 2,658,926,675.27[20] - The company’s total equity rose to CNY 2,236,668,672.14 from CNY 2,204,604,085.51[21] - Owner's equity attributable to shareholders increased by 1.57% to CNY 2,214,587,509.95 from CNY 2,180,294,683.75 at the end of the previous year[3] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 49,564[8] - The top shareholder, Lu Nan, holds 7.24% of the shares, totaling 62,739,500 shares[8] - The company repurchased a total of 33,497,450 shares, accounting for 3.87% of the total share capital, with a total transaction amount of RMB 229,612,367.24[15] - The highest transaction price during the share repurchase was RMB 7.08 per share, while the lowest was RMB 6.48 per share[15] Expenses - Total operating costs amounted to CNY 363,464,962.64, compared to CNY 309,189,573.52 in the prior period, reflecting a significant increase[22] - Financial expenses surged by 1323.58% to CNY 25,110,582.49, primarily due to increased convertible bond interest expenses[6] - Research and development expenses were CNY 31,781,348.68, showing a decrease from CNY 33,341,951.70 in the last period[22] - The company paid CNY 119,083,407.65 to employees, an increase from CNY 102,007,292.10 in the previous period[27] Investments - Development expenditures rose by 64.92% to CNY 9,385,571.94, reflecting ongoing investment in development projects[6] - The long-term equity investments increased to CNY 402,435,736.46 from CNY 400,277,572.33[21] - Cash inflows from investment activities were CNY 39,269,956.84, significantly lower than CNY 174,646,697.43 in the previous period[27] Convertible Bonds - The company completed the distribution of interest for its convertible bonds, with a total interest payment of RMB 3,267,783.60 for the period[12] - As of March 31, 2022, the company had 8,169,288 convertible bonds remaining, with a total remaining amount of RMB 816,928,800[13]